Juvenile Diabetes Research Foundation Canada

2550 Victoria Park Avenue, Suite 800
Toronto, ON M2J 5A9
President & CEO: Dave Prowten
Board Chair: Aubrey Baillie

Website: www.jdrf.ca
Charitable Reg. #: 11897 6604 RR0001
Sector: Health
Operating Charity

Social Results Reporting

Grade: B

The grade is based on the charity's public reporting of the work it does and the results it achieves.

Financial Transparency

Audited financial statements for current and previous years available on the charity's website [ Audited financial statement for most recent year ]

Program Cost Coverage

Funding Reserves Program Costs

Spending Breakdown

Full-time staff #89

Avg. Compensation $79,671

Top 10 Staff Salary Range

$350k + 0
$300k - $350k 0
$250k - $300k 0
$200k - $250k 1
$160k - $200k 0
$120k - $160k 3
$80k - $120k 6
$40k - $80k 0
< $40k 0
Information from most recent CRA Charities Directorate filings for F2013

About Juvenile Diabetes Research Foundation Canada:

Founded in 1974 by parents of children with diabetes, Juvenile Diabetes Research Foundation Canada (JDRF) is the largest funder and advocate for Type 1 diabetes (T1D) research. Its focus is to find a cure for T1D and its complications. JDRF reports that 300,000 Canadians live with T1D. On average, this requires 1,460 insulin shots a year to manage T1D. T1D often leads to life-threatening and debilitating complications which may include kidney failure, blindness, heart disease, stroke, nerve damage and amputation. T1D is rising in its frequency among children under the age of 14, with rates doubling over the last 20 years in children younger than 5 years old. JDRF funds research across a broad portfolio in 4 areas – immune therapies, beta cell therapies, glucose control, and complication therapies.

From 2010-2013 the Federal Government granted $20m for clinicial T1D research. JDRF gave $13.9m and another major donation recently gave $3m. This funding launched 9 clinical trials and 2 technology projects involving more than 100,000 Canadians in research. This research included the artificial pancreas, a revolutionary advance in diabetes care. In 2014, the artificial pancreas got USFDA approval. JDRF's other research milestones are beta cell encapsulation (implanting stem cells to "heal" T1D with the first human trial underway in 2014), and smart insulin in a nasal spray that may prevent T1D onset.

Financial Review:

JDRF's fundraising costs are 46.8% of donations. Fundraising costs are $11.3m, a $3.6m increase in 2013. JDRF spends more on fundraising that it does on T1D programs and research. This is due to high-cost fundraising events: the stationary bike-a-thon held in 22 Canadian cities brings corporations together in friendly competition grossing $6.8m, the Telus Walk in 70 sites across Canada grosses almost $7.7m and 3,400 people attend galas grossing over $3.5m. These events account for 75% of JDRF's revenues. Administrative costs are 8.2% of revenues. JDRF has funding reserves of $12.7m covering annual program costs and grants 1.4 times (140%).

Updated: February 24, 2015 by Kate Bahen.

Financial Ratios

Fiscal year ending December
Administrative costs as % of revenues 8.2%6.7%6.9%
Fundraising costs as % of donations 46.8%32.9%31.3%
Program cost coverage (%) 139.7%33.0%52.9%

Summary Financial Statements

All figures in $000s
Donations 24,16423,34024,918
Government funding 06,35515,806
Lotteries (net) 428116104
Investment income 30111171
Total revenues 24,62229,92241,000
Program costs 3,77123,36224,530
Grants 5,33400
Administrative costs 2,0261,9872,795
Fundraising costs 11,3117,6777,791
Cash flow from operations 2,179(3,103)5,883
Funding reserves 12,7197,70112,983
Note: JDRF reports "direct expenses" for fundraising costs that are included in fundraising. Ci has restated revenues gross of these costs of $5.0m in 2013, $4.7m in 2012, $5.0m in 2011. Ci has included a deferred donation of $1.1m in 2013 with donations received.

Comments added by the Charity:

These comments refer to a previous Charity Intelligence profile:

JDRF directs funds to deliver both near-term benefits for people who live with type 1 diabetes and, ultimately, a cure. Our research focus is on two distinct and related aims of science leading to a cure and science leading to better treatments. JDRF also provides outreach support services, volunteer and advocacy opportunities.

Canada’s excellence in diabetes research and breakthroughs continues in the creation of the JDRF Canadian Clinical Trial Network. Launched in 2010 through a partnership with the Government of Canada, JDRF CCTN began as a $33.9M investment to accelerate the testing of new technologies and treatments for Canadians living with type 1 diabetes and its complications.

JDRF is positively impacting the lives and futures of people living with diabetes. Thanks to the support of our generous donors, JDRF has made significant advancements and progress toward positive health outcomes for people living with type 1 diabetes. For example:

  • JDRF-funded research with industry partners on immune therapies is progressing to the most advanced stages of clinical testing
  • JDRF now funds over 50 human clinical trials, as opposed to five in 2003.
  • JDRF is perfecting insulin treatments, a critical component of JDRF’s Artificial Pancreas Project and impact on the daily lives of those living with type 1 diabetes.
  • Recent advances in diabetic eye disease, funded in part by JDRF, hold the potential to help prevent and reverse eye disease in people with type 1 diabetes.

We remain committed to a cure while investing in better treatments for today.

Go to top